Financing Healthcare and Life Sciences

In a highly innovative pharma and medical device environment generating many biotechnology entities, funding and merging matters have been on the rise.

Our international life sciences team has built strong relationships with leading financial institutions and investors in the sector.

Access to capital from VCs, private equity and the capital markets is of crucial importance to the development of successful biotechs. However, in addition to the economic rationale for investment and M&A, our experience shows that when investing in biotechs many investors and strategic partners also rely on the quality of management and business relationships when considering which companies to invest in.

Our in-depth knowledge of the life sciences sector, together with the strength of our relationships with a wide variety of global industry stakeholders is a rare quality in a law firm and one which banks and investors tell us adds real value to their transactions.

We advise many of the largest global pharmaceutical companies and leading medical device manufacturers. We also act for small and medium-sized enterprises, financial institutions, investors, universities and governments, elsewhere across the pharma, medical device, consumer health, digital health and healthcare services sub-sectors.

Our international M&A team assists with

• Corporate funds
• Asset management
• Investments
• Domestic and international transactions
• Public take overs and auction sales
• Demergers
• Corporate restructurings
• Joint ventures and strategic alliances

Our cross-border equity capital markets team assists with

• Local and international ECM transactions
• IPOs
• Secondary offerings
• Block trades
• Pre-IPO
• Private placements
• Convertible and exchangeable bond issues
• International equity offerings with a focus on Rule 144A private placements and Regulation D private placements.